Current progress in pharmacologic treatment strategies for alcohol dependence

Expert Review of Clinical Pharmacology

Volumn 5, Issue 4, 2012, Pages 427-435

  Clapp, Peter ^a  

^a REGIS UNIVERSITY   (United States)

Author keywords

abstinence; acamprosate; alcohol dependence; craving; disulfiram; naltrexone

Indexed keywords

ACAMPROSATE; ACETALDEHYDE; ALCOHOL; ALDEHYDE DEHYDROGENASE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DISULFIRAM; DOPAMINE BETA MONOOXYGENASE; MU OPIATE RECEPTOR; NALTREXONE; NICOTINE PATCH; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ALCOHOL ABSTINENCE; ALCOHOL INTOXICATION; ALCOHOL METABOLISM; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANTICIPATION; COMORBIDITY; DIARRHEA; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DEPENDENCE TREATMENT; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HYPOTENSION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LIVER TOXICITY; LOW DRUG DOSE; MORBIDITY; MORTALITY; MOTIVATION; NAUSEA AND VOMITING; NEUROBIOLOGY; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SWEATING; TACHYCARDIA; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

ALCOHOL DETERRENTS; ALCOHOLISM; ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DRUG DESIGN; HUMANS; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; UNITED STATES;

EID: 84866134915     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.31     Document Type: Review

References (69)

1. Clapp P, Bhave SJ, Hoffman PL. How adaptation of the brain to alcohol leads to dependence. Alcohol Res. Health. 31(4), 310-339 (2008).
2. Lovinger DM. Communication networks in the brain. Alcohol Res. Health. 31(3), 196-214 (2008).
3. Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl.) 139(1-2), 2-19
4. De Witte P, Pinto E, Ansseau M, Verbanck P. Alcohol and withdrawal: From animal research to clinical issues. Neurosci. Biobehav. Rev. 27(3), 189-197 (2003).
5. Koob GF. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56(Suppl. 1), 18-31
6. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA 281(14), 1318-1325 (1999).
7. Williams EE. Effects of alcohol on workers with carbon disulfide. JAMA 109, 1472
8. Martensen-Larsen O. Treatment of alcoholism with a sensitizing drug. Lancet 2(6539), 1004 (1948).
9. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta. Psychiatr. Scand. 86, 15-26 (1992).
10. Skinner MD, Coudert M, Berlin I, Passeri E, Michel L, Aubin HJ. Effect of the threat of a disulfiram-ethanol reaction on cue reactivity in alcoholics. Drug Alcohol Depend. 112(3), 239-246 (2010).
11. Chen WJ, Loh EW, Hsu YP, Cheng AT. Alcohol dehydrogenase and aldehyde dehydrogenase genotypes and alcoholism among Taiwanese aborigines. Biol. Psychiatry 41(6), 703-709 (1997).
12. Gaval-Cruz M, Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: Antabuse and cocaine relapse. Mol. Interv. 9(4), 175-187 (2009).
13. Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93(5), 713-727 (1998).
14. Goldstein M, Nakajima K. The effect of disulfiram on catecholamine levels in the brain. J. Pharmacol. Exp. Ther. 157(1), 96-102 (1967).
15. Mutschler J, Dirican G, Funke S et al. Experienced acetaldehyde reaction does not improve treatment response in outpatients treated with supervised disulfiram. Clin. Neuropharmacol. 34(4), 161-165 (2011).
16. Disulfiram, prescribing information. AHFS Drug Information®, Bethesda, MD, USA (2011).
17. Mutschler J, Dirican G, Gutzeit A, Grosshans M. Safety and efficacy of long-term disulfiram aftercare. Clin Neuropharmacol. 34(5), 195-198 (2011).
18. Fuller RK, Branchey L, Brightwell DR et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 256(11), 1449-1455 (1986).
19. Chick J, Gough K, Falkowski W et al. Disulfiram treatment of alcoholism. Br. J. Psychiatry 161, 84-89 (1992).
20. Palatty PL, Saldanha E. Status of disulfiram in present day alcoholic deaddiction therapy. Indian J. Psychiatry 53(1), 25-29 (2011).
21. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B; VA New England VISN I MIRECC Study Group. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol. Psychiatry 57(10), 1128-1137 (2005).
22. Roache JD, Kahn R, Newton TF et al. A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram. Drug Alcohol Depend. 119(1-2), 37-45 (2011).
23. Marinelli PW, Quirion R, Gianoulakis C. Estradiol valerate and alcohol intake: A comparison between Wistar and Lewis rats and the putative role of endorphins. Behav. Brain Res. 139(1-2), 59-67 (2003).
24. Gianoulakis C. Alcohol-seeking behavior: The roles of the hypothalamic-pituitary-adrenal axis and the endogenous opioid system. Alcohol Health Res. World 22(3), 202-210 (1998).
25. Vivitrol® (naltrexone for extended-release injectable suspension), prescribing information. Alkermes, MA, USA (2009).
26. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O'Malley SS. Family history of alcoholism influences naltrexoneinduced reduction in alcohol drinking. Biol. Psychiatry 62(6), 694-697
27. Anton RF. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics 9(6), 655-658 (2008).
28. Gelernter J, Gueorguieva R, Kranzler HR et al.; VA Cooperative Study #425 Study Group. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: Results from the VA Cooperative Study. Alcohol. Clin. Exp. Res. 31(4), 555-563 (2007).
29. Anton RF, O'Malley SS, Ciraulo DA et al.; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA 295(17), 2003-2017 (2006).
30. Anton RF, Oroszi G, O'Malley S et al. An evaluation of μ-opioid receptor (OPRM1 as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65(2), 135-144 (2008).
31. Litten RZ, Allen JP. Advances in development of medications for alcoholism treatment. Psychopharmacology (Berl. (1-2), 20-33 (1998).
32. Garbutt JC, Kranzler HR, O'Malley SS et al.; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA 293(13), 1617-1625 (2005).
33. O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcoholdependent patients who are abstinent before treatment. J. Clin. Psychopharmacol. 27(5), 507-512 (2007).
34. Pettinati HM, O'Brien CP, Rabinowitz AR et al. The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. J. Clin. Psychopharmacol. 26(6), 610-625 (2006).
35. Richardson K, Baillie A, Reid S et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction 103(6), 953-959
36. Gulliver SB, Rohsenow DJ, Colby SM et al. Interrelationship of smoking and alcohol dependence, use and urges to use. J. Stud. Alcohol 56(2), 202-206 (1995).
37. Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs 21(3), 213-237 (2007).
38. King A, Cao D, Vanier C, Wilcox T. Naltrexone decreases heavy drinking rates in smoking cessation treatment: An exploratory study. Alcohol. Clin. Exp. Res. 33(6), 1044-1050 (2009).
39. O'Malley SS, Krishnan-Sarin S, McKee SA et al. Dose-dependent reduction of hazardous alcohol use in a placebocontrolled trial of naltrexone for smoking cessation. Int. J. Neuropsychopharmacol. 12(5), 589-597 (2009).
40. Spanagel R, Zieglgänsberger W. Anticraving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol. Sci. 18(2), 54-59 (1997).
41. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs 19(6), 517-537 (2005).
42. Harris BR, Prendergast MA, Gibson DA et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol. Clin. Exp. Res. 26(12), 1779-1793
43. Umhau JC, Momenan R, Schwandt ML et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: A randomized controlled experimental medicine study. Arch. Gen. Psychiatry 67(10), 1069-1077 (2010).
44. Littleton J, Zieglgänsberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am. J. Addict. 12(Suppl. 1), S3-11 (2003).
45. Rammes G, Mahal B, Putzke J et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40(6), 749-760 (2001).
46. Mann K. Pharmacotherapy of alcohol dependence: A review of the clinical data. CNS Drugs 18(8), 485-504 (2004).
47. Schädlich PK, Brecht JG. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study. Pharmacoeconomics 13(6), 719-730 (1998).
48. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. J. Psychiatr. Res. 40(5), 383-393 (2006).
49. Kranzler HR, Gage A. Acamprosate efficacy in alcohol-dependent patients: Summary of results from three pivotal trials. Am. J. Addict. 17(1), 70-76 (2008).
50. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcohol. Clin. Exp. Res. 28(1), 51-63 (2004).
51. Gueorguieva R, Wu R, Donovan D et al. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug Alcohol Depend. 107(2-3), 221-229 (2010).
52. Diehl A, Ulmer L, Mutschler J et al. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. Alcohol Alcohol. 45(3), 271-277
53. Laaksonen E, Koski-Jännes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 43(1), 53-61 (2008).
54. de Sousa A, de Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 40(6), 545-548 (2005).
55. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcohol. Clin. Exp. Res. 22(3), 573-579 (1998).
56. Bouza C, Angeles M, Magro A, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 99(7), 811-828 (2004).
57. Kiefer F, Jahn H, Tarnaske T et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebocontrolled study. Arch. Gen. Psychiatry 60(1), 92-99 (2003).
58. • First controlled study comparing and combining naltrexone and acamprosate treatments for relapse prevention. 58 Feeney GF, Connor JP, Young RM, Tucker J, McPherson A. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: A single centres' experience with pharmacotherapy. Alcohol Alcohol. 41(3), 321-327 (2006).
59. Kiefer F, Wiedemann K. Combined therapy: What does acamprosate and naltrexone combination tell us? Alcohol Alcohol. 39(6), 542-547 (2004).
60. Kranzler HR. Extended-release intramuscular naltrexone: A viewpoint by Henry R Kranzler. Drugs 66(13), 1753-1754 (2006).
61. Anton RF, Myrick H, Wright TM et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am. J. Psychiatry 168(7), 709-717
62. Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: An open-label controlled study. BMC Psychiatry 11, 41 (2011).
63. Flórez G, Saiz PA, García-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the treatment of alcohol dependence: Comparison with naltrexone. Eur. Addict. Res. 17(1), 29-36 (2011).
64. Mann K, Hermann D. Individualised treatment in alcohol-dependent patients. Eur. Arch. Psychiatry Clin. Neurosci. 260(Suppl. 2), S116-S120 (2010).
65. Kranzler HR, Armeli S, Tennen H et al. A double-blind, randomized trial of sertraline for alcohol dependence: Moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J. Clin. Psychopharmacol. 31(1), 22-30
66. Johnson BA, Ait-Daoud N, Seneviratne C et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 168(3), 265-275 (2011).
67. Roache JD, Wang Y, Ait-Daoud N, Johnson BA. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism. Alcohol. Clin. Exp. Res. 32(8), 1502-1512
68. Schumann G, Coin LJ, Lourdusamy A et al. Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumption. Proc. Natl Acad. Sci. USA 108(17), 7119-7124 (2011).
69. Project Match Research Group. Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J. Stud. Alcohol. 58, 7-29 (1997).